Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases
21 large-cap stocks that are down at least 20% in 2016
UPDATE: 21 large-cap stocks that are down at least 20% in 2016
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Options on this firm's blockbuster cost a little but pay off big.